Analysts say that Vioxx has had a significant effect on drug approvals
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Supplementary information
Rights and permissions
About this article
Cite this article
Frantz, S. 2005 approvals: Safety first. Nat Rev Drug Discov 5, 92–93 (2006). https://doi.org/10.1038/nrd1973
Issue Date:
DOI: https://doi.org/10.1038/nrd1973